Cyteir Therapeutics, Inc. (CYT) News
Filter CYT News Items
CYT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest CYT News From Around the Web
Below are the latest news stories about CYTEIR THERAPEUTICS INC that investors may wish to consider to help them evaluate CYT as an investment opportunity.
Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety ProfileLEXINGTON, Mass., October 12, 2023--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT) today presented ongoing results from a dose expansion cohort in its Phase 1 combination study of CYT-0851 with capecitabine in patients with platinum-refractory or -resistant ovarian cancer in a late-breaker poster titled "Phase 1 Dose Expansion Results of CYT-0851, a Monocarboxylate Transporter (MCT) Inhibitor, in Combination with Capecitabine in Platinum-Resistant Ovarian Cancer" (Poster: LB_A13) at the 2023 |
Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and DissolutionLEXINGTON, Mass., June 30, 2023--Cyteir Therapeutics, Inc. ("Cyteir" or the "Company") (Nasdaq: CYT) today announced that it is discontinuing all development of CYT-0851, its investigational monocarboxylate transporter inhibitor, and that Cyteir’s Board of Directors has determined, after consideration of potential strategic alternatives, it is in the best interests of its shareholders to dissolve Cyteir, liquidate its assets following an orderly wind down of the Company’s operations, and return |
Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety ProfileLEXINGTON, Mass., June 03, 2023--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a clinical stage oncology company, today presented results from a Phase 1 study with CYT-0851 in combination with capecitabine or gemcitabine in a poster titled "Phase 1 Results of CYT-0851, a Monocarboxylate Transporter (MCT) Inhibitor, in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors" (Abstract: 3099, Poster: 297) at the 2023 American Society of Clinical Oncology (ASCO) annual meeting i |
Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational HighlightsLEXINGTON, Mass., May 10, 2023--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a clinical stage oncology company, today reported financial results for the first quarter ended March 31, 2023 and provided an update on recent operational highlights. |
Insiders who bought Cyteir Therapeutics, Inc. (NASDAQ:CYT) last year must be regretting not buying more as market cap hits US$72mCyteir Therapeutics, Inc. ( NASDAQ:CYT ) insiders who purchased shares in the last 12 months were richly rewarded last... |
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational HighlightsLEXINGTON, Mass., March 23, 2023--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a clinical stage oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on recent operational highlights. |
Cyteir Therapeutics Promotes David Gaiero to Chief Financial OfficerLEXINGTON, Mass., February 06, 2023--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT) a clinical stage oncology company today announced the promotion of David Gaiero to Chief Financial Officer (CFO). David was previously Vice President of Finance at Cyteir. As CFO, David will continue to manage the finance department, to oversee the company’s overall financial operations, and to help drive the long-term business and financial strategy of Cyteir, reporting directly to the President & CEO. |
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash RunwayLEXINGTON, Mass., January 19, 2023--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT) today announced the strategic prioritization of clinical development of CYT-0851, an investigational monocarboxylate transporter inhibitor, as a potential combination therapy for the treatment of ovarian cancer. The prioritization follows encouraging preliminary clinical activity in a small number of patients observed in the Phase 1 dose escalation cohort with CYT-0851 in combination with capecitabine in advan |